Does heparin reduce thromboembolic complications in patients with acute myocardial infarction?
This study investigates the clinical utility of heparin for anticoagulation following acute myocardial infarction.
HEPARIN has been proved an effective agent for the prevention of intravascular thrombosis in laboratory animals1 and is more effective than bis-hydroxycoumarin in preventing thrombosis of stagnant, venous blood.2 Despite these and other3 suggestions that it should decrease thromboembolic complications, heparin has had only one major clinical trial in patients with acute myocardial infarction,4 whereas bishydroxycoumarin and its congeners have been extensively studied.5 This report concerns a study of anticoagulation with heparin after acute myocardial infarction.Material and MethodsAll patients with a tentative admission diagnosis of acute (less than forty-eight hours old) myocardial infarction admitted to the Second and . . .
Carleton et al. (Thu,) studied this question.